Patient’s Perspectives Important for Early Anti-Tumor Necrosis Factor Treatment in Inflammatory Bowel Disease

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Inflammatory Bowel ◽

Necrosis Factor ◽

Sa1897 Anti-Tumor Necrosis Factor Treatment of Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

Gastroenterology ◽

10.1016/s0016-5085(16)31386-5 ◽

2016 ◽

Vol 150 (4) ◽

pp. S396-S397 ◽

Cited By ~ 1

Author(s):

Ramprasad Jegadeesan ◽

Gursimran Kochhar ◽

Umar Hayat ◽

Ahyoung J. Kim ◽

Nan Lan ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Primary Sclerosing Cholangitis ◽

Bowel Disease ◽

Sclerosing Cholangitis ◽

Tumor Necrosis ◽

Inflammatory Bowel ◽

Necrosis Factor ◽

Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment

Journal of Gastroenterology and Hepatology ◽

10.1111/jgh.14019 ◽

2017 ◽

Vol 33 (1) ◽

pp. 20-29 ◽

Cited By ~ 4

Author(s):

Dong II Park ◽

Tadakazu Hisamatsu ◽

Minhu Chen ◽

Siew Chien Ng ◽

Choon Jin Ooi ◽

...

Keyword(s):

Risk Assessment ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Tuberculosis Infection ◽

Inflammatory Bowel ◽

Asian Pacific ◽

Necrosis Factor ◽

Mycobacterium tuberculosis infection in patients with inflammatory bowel disease who received Anti-Tumor Necrosis Factor treatment in Russia

10.1183/13993003.congress-2020.482 ◽

2020 ◽

Author(s):

Xenia Frolova ◽

Serge Borisov

Keyword(s):

Mycobacterium Tuberculosis ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Tuberculosis Infection ◽

Mycobacterium Tuberculosis Infection ◽

Inflammatory Bowel ◽

Necrosis Factor ◽

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment

Intestinal Research ◽

10.5217/ir.2018.16.1.4 ◽

2018 ◽

Vol 16 (1) ◽

pp. 4 ◽

Cited By ~ 8

Author(s):

Dong Il Park ◽

Tadakazu Hisamatsu ◽

Minhu Chen ◽

Siew Chien Ng ◽

Choon Jin Ooi ◽

...

Keyword(s):

Risk Assessment ◽

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Tuberculosis Infection ◽

Asia Pacific ◽

Inflammatory Bowel ◽

Necrosis Factor ◽

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management

Intestinal Research ◽

10.5217/ir.2018.16.1.17 ◽

2018 ◽

Vol 16 (1) ◽

pp. 17 ◽

Cited By ~ 10

Author(s):

Dong Il Park ◽

Tadakazu Hisamatsu ◽

Minhu Chen ◽

Siew Chien Ng ◽

Choon Jin Ooi ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Tuberculosis Infection ◽

Asia Pacific ◽

Inflammatory Bowel ◽

Necrosis Factor ◽

Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor- treatment

Haematologica ◽

10.3324/haematol.2009.009985 ◽

2009 ◽

Vol 95 (2) ◽

pp. 199-205 ◽

Cited By ~ 94

Author(s):

G. Bergamaschi ◽

A. Di Sabatino ◽

R. Albertini ◽

S. Ardizzone ◽

P. Biancheri ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Inflammatory Bowel ◽

Necrosis Factor ◽

Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management

Journal of Gastroenterology and Hepatology ◽

10.1111/jgh.14018 ◽

2017 ◽

Vol 33 (1) ◽

pp. 30-36 ◽

Cited By ~ 8

Author(s):

Dong Il Park ◽

Tadakazu Hisamatsu ◽

Minhu Chen ◽

Siew Chien Ng ◽

Choon Jin Ooi ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Tuberculosis Infection ◽

Asia Pacific ◽

Inflammatory Bowel ◽

Necrosis Factor ◽

Optimizing Anti-tumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease with Therapeutic Drug Monitoring

Journal of Pediatric Gastroenterology and Nutrition ◽

10.1097/mpg.0000000000002704 ◽

2020 ◽

Vol Publish Ahead of Print ◽

Author(s):

Isabel Pinto-Pais ◽

Maria Céu Espinheira ◽

Eunice Trindade ◽

Jorge Amil-Dias

Keyword(s):

Tumor Necrosis Factor ◽

Therapeutic Drug Monitoring ◽

Bowel Disease ◽

Tumor Necrosis ◽

Therapeutic Drug ◽

Pediatric Inflammatory Bowel Disease ◽

Inflammatory Bowel ◽

Necrosis Factor ◽

Faculty Opinions recommendation of Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727471255.793531335 ◽

2017 ◽

Author(s):

Sanjiv Luther

Keyword(s):

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Intestinal Inflammation ◽

Oncostatin M ◽

Inflammatory Bowel ◽

Necrosis Factor

Faculty Opinions recommendation of Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727471255.793531087 ◽

2017 ◽

Author(s):

Lars Rogge

Keyword(s):

Tumor Necrosis Factor ◽

Bowel Disease ◽

Tumor Necrosis ◽

Intestinal Inflammation ◽

Oncostatin M ◽

Inflammatory Bowel ◽

Necrosis Factor